To market and sell its offerings for preclinical in vivo fluorescence imaging, Grenoble, France-based Fluoptics has opened an office in Cambridge, Mass. The company develops solutions that combine a nonradioactive fluorescent tracer targeting cancer cells with its Fluobeam real-time optical imaging system. The device, due to enter clinical trials this year in Europe, is available to the preclinical research market. “We will now work on accelerating the distribution of our preclinical instruments in the US and Canada directly or through key partnerships,” said Odile Allard, CEO of Fluoptics. The technology will illuminate cancer cells in real time during surgery.